StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) stock

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)

Close on Nov 17, 2026Market cap $278.95MP/E –Yield –

Eikon Therapeutics cash

Cash and short-term investments held at the end of each period.

Eikon Therapeutics's cash was $531.18M at Jun 30, 2026. For fiscal 2025 it was $335.98M.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$335.98M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$531.18M+159.6%
Q1 FY2026Mar 31, 2026$512.18M–
Q4 FY2025Dec 31, 2025$335.98M–
Q2 FY2025Jun 30, 2025$136.56M–
Q1 FY2025Mar 31, 2025$204.58M–

More Eikon Therapeutics figures

See a number that looks wrong?